NicOx : Garufi ... e la Rivoluzione Pharma (2 lettori)

Stato
Chiusa ad ulteriori risposte.

DickSIM

Prima o poi....ci becco!
ATTENZIONEEEEEEEEEE MERCK NUOVAMENTE SOPRA I 30$ :cool:

OPA ORMAI PROSSIMA!!!!! concambio fissato 1:1 e siamo a posto!
avvisate tutti!!!!!!
zombie46ni.gif
zombie46ni.gif
zombie46ni.gif
zombie46ni.gif


telephone-cellulaire-9305.gif
telephone-cellulaire-9305.gif
telephone-cellulaire-9305.gif
avvisate l'AMCOX e gli svizzeri!!!!!!!


MDR-mort-de-rire.gif
MDR-mort-de-rire.gif
MDR-mort-de-rire.gif
 

DickSIM

Prima o poi....ci becco!
Comunque qui qualcosa non quadra ... fase laterale con prezzi bassi e bloccati su range determinati, avendo una molecola praticamente approvata ... :specchio: :titanic: :-?

:wall::wall::wall::D ecco qui per gli amanti dell'OPA una OPA FRESCA FRESCA DI GIORNATA :D

A wave of merger-and-acquisition activity gave investor confidence a boost early Thursday. Bristol-Myers Squibb Co. said late Wednesday it is buying Medarex Inc. for about $2.1 billion in cash, the latest in a string of acquisitions by the drugmaker.
The New York-based company said it will pay $16 a share for Medarex, a 90 percent premium over Medarex's closing share price Wednesday of $8.40. Medarex shares nearly doubled in premarket trading, jumping $7.49 to $15.89.


vi allego anche un bel grafico dell'ultimo anno dal quale si evince chiaramente , visto l'andazzo, che era un titolo chiaramente sotto TIRO :censored: :lol::lol::lol::lol::lol::help::help:
 

Allegati

  • op.jpg
    op.jpg
    40,4 KB · Visite: 125

Netzach

Forumer storico
Nicox : Portzamparc livre ses prévisions sur la trésorerie
Jeudi 23 juillet 2009 à 16:22

(Tradingsat.com) - A l'approche de la publication des résultats semestriels de NicOx mercredi prochain 29 juillet 2009, Portzamparc a fait jeudi le point sur ses attentes.

La société de Bourse sera en particulier attentive au niveau de la trésorerie de la société de biotechnologie qu'elle anticipe proche de 75 millions d'euros, contre 84,6 millions d'euros au 31 mars 2009.

Portzamparc estime ainsi que la consommation de trésorerie a été de l'ordre de 10 millions d'euros au deuxième trimestre, tout en signalant que le cash burn est difficile à estimer. Il dépend en effet de trois facteurs : les versements liés aux études cliniques, les versements du crédit d'impôt recherche, ainsi que l'activité commerciale.
 

DickSIM

Prima o poi....ci becco!
Biotech americane in grande spolvero............

Racing to beat Novartis to the world's biggest drug markets with a new oral therapy for multiple sclerosis, Merck KGaA has filed for regulatory approval of cladribine in Europe and plans to file in the U.S. later this quarter.

The application brings Merck "closer to the possibility of providing an oral short-course treatment to patients with multiple sclerosis," Executive Vice President Roberto Gradnik said in a statement. Last spring researchers reported that cladribine cut the risk of relapse in half, though some patients also experienced a depletion of white blood cells needed to protect them from infections. The therapy works by blunting the human immune system.

Analysts say that cladribine is likely to achieve blockbuster status, with a billion dollars in annual sales. "A market entry in Europe beginning of 2010 seems feasible, as should be the case for the U.S.," wrote analysts for DZ Bank AG.:D
 
Stato
Chiusa ad ulteriori risposte.

Users who are viewing this thread

Alto